Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers
about
Management of hemolytic-uremic syndrome in childrenShiga Toxin (Stx) Classification, Structure, and FunctionMonoclonal antibody-based therapies for microbial diseasesAntibodies for biodefenseBaicalin inhibits the lethality of ricin in mice by inducing protein oligomerization.Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.Recent advances in understanding enteric pathogenic Escherichia coli.Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial GhostsBaicalin inhibits the lethality of Shiga-like toxin 2 in mice.Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?Diminazene aceturate: an antibacterial agent for Shiga-toxin-producing Escherichia coli O157:H7.Targeting pili in enterococcal pathogenesis.Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.Shiga toxins: from structure and mechanism to applications.Isolation of B subunit-specific monoclonal antibody clones that strongly neutralize the toxicity of Shiga toxin 2.Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Shiga Toxin Therapeutics: Beyond Neutralization.Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic DesignThrombotic microangiopathies
P2860
Q27002576-7DC89A94-9EB0-4AEC-B763-3AAAA1E18DF8Q27021676-39BEC468-F143-4D6D-9868-E6D807A55844Q27490830-6F05F08A-703B-4C8E-AF26-15ECF21C621BQ28394941-6F51FD77-6AE6-4164-9183-E2A5D202002EQ30373440-D195A39D-0D34-4EB0-BCA5-887C0BAF9055Q33404149-806E4D12-93F8-48DE-8483-53CC6E3EB561Q34375210-74350C7E-94D8-4F02-8E77-8E2DF83CCFF0Q35221158-71E8FB97-3F10-42A7-B638-1DC09F9ACCA8Q35947400-8774D6F2-C61A-4DF9-BBCA-2F9961E8D2B3Q36158351-616CBE5E-83FA-442D-8B77-295B8948B3F7Q36841541-0E7048EC-1CF2-4448-ADD5-BCC7467FF844Q37064733-0F51DE28-1957-4DF8-9912-78D4FDF06A7BQ37354260-983D062F-EEA5-485A-8921-92A83D69AABAQ37713275-C4556C4E-E2F9-4877-9942-5B4045A50CA1Q38024274-952F703F-55CF-4A5F-B99F-6BA6A0286358Q38674171-15D17810-560A-494B-A1BF-BEBB9013C20DQ38927469-A0BADB80-25CC-4A7B-A655-667C2E0FFD0DQ39197564-76747EC7-93DA-42A1-BE5C-41BE3A9F8FB3Q41669177-01E612A8-547B-4B03-A29E-421FDB98F813Q53696162-BFBB164D-3565-414C-BBEB-3BE626525FA8Q57946303-2DF179BA-D8A5-49A4-8A68-BC4153C268FCQ58690782-8A496F60-8DF2-4408-9B37-44671B89A8B1
P2860
Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and pharmacokinetics of ...... tibodies in healthy volunteers
@en
Safety and pharmacokinetics of ...... ibodies in healthy volunteers.
@nl
type
label
Safety and pharmacokinetics of ...... tibodies in healthy volunteers
@en
Safety and pharmacokinetics of ...... ibodies in healthy volunteers.
@nl
prefLabel
Safety and pharmacokinetics of ...... tibodies in healthy volunteers
@en
Safety and pharmacokinetics of ...... ibodies in healthy volunteers.
@nl
P2093
P2860
P356
P1476
Safety and pharmacokinetics of ...... tibodies in healthy volunteers
@en
P2093
Catherine Brockus
Claire Thuning-Roberson
Eric Sicard
Marc Rivière
Mariam Mehran
Martin Bitzan
Ruth Poole
P2860
P304
P356
10.1128/AAC.01661-08
P407
P577
2009-05-04T00:00:00Z